Wanbury Limited, the fastest growing pharmaceutical company in India, has reported net sales of Rs 86.38 crore for the quarter ended on September 30, 2009, compared to Rs 92.04 crore in the corresponding quarter of last fiscal. The net profit was Rs 2.95 crore, compared to Rs 6.57 crore in the corresponding quarter of last fiscal.
EPS for Q2F Y10 worked out to Rs 2.01 as against Rs 4.47 in Q2 FY09.
Wanbury had a Compounded Annual Growth Rate (CAGR) of 68 per cent over the last six years. The company has strong presence in domestic formulations, API and Contract Research and Manufacturing Services (CRAMS). It also has presence in Europe in Formulations. Wanbury offers the life science industry best in class services related to research, development and manufacturing of chemicals, intermediates, API and finished forms. The company has fast growing presence in CRAMS catering to large MNCs globally for manufacturing their products. Wanbury has its sales office in Zurich, Switzerland and caters to US and European markets through its US FDA plants.